Monte Rosa Therapeutics, Inc.
NASDAQ Global SelectCapital Structure
•
in mil. unless spec.Working Capital
•
in mil. unless spec.Growth Rates
•
in mil. unless spec.Quarterly Revenue
•
in mil. unless spec.Quarterly Earnings Per Share
•
in mil. unless spec.Quarterly Dividends Per Share
•
in mil. unless spec.Company Description
- CEO
- Markus Warmuth
- Full Time Employees
- 173
- Sector
- Healthcare
- Industry
- Biotechnology
- Address
- 321 Harrison Avenue Boston MA United States of America 02118
- IPO Date
- Jun 24, 2021
- CIK
- 0001826457
- Website
- monterosatx.com
- Similar Companies
- Business
- Monte Rosa Therapeutics, Inc. is a clinical-stage biotechnology company primarily engaged in the discovery and development of novel therapeutics to address rare diseases and immuno-oncology conditions. The company specializes in producing small molecule drug candidates that target molecular pathways involved in immune regulation and inflammatory diseases. Key product categories include precision immunotherapies, with a platform leveraging translational biology, chemistry, and clinical expertise to identify and advance therapies modulating immune responses. Monte Rosa Therapeutics focuses on developing treatments for patients with serious medical conditions with unmet needs. Headquartered in Dallas, Texas, and founded recently, the company operates within the biotechnology and pharmaceutical industry, serving global markets through clinical development programs. Monte Rosa Therapeutics targets investors, clinicians, and researchers interested in innovative treatments for immune-related diseases and rare disorders. The latest major company changes include strategic partnerships with leading research institutions and pharmaceutical companies to accelerate drug discovery and development. Monte Rosa Therapeutics has recently expanded its pipeline through novel product launches and entered collaborations to enhance clinical trial capabilities. The company has not announced any recent name changes or reorganization but has positioned itself for growth by broadening therapeutic focuses and strengthening its scientific and operational platform within the last 1-2 years. These efforts emphasize Monte Rosa Therapeutics' commitment to advancing precision medicines from discovery through clinical development to commercialization.
Company News
Monte Rosa Therapeutics: High-Stakes Drug Pipeline Balanced By A Fortress Balance Sheet
Monte Rosa Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
Monte Rosa Therapeutics to Participate in Upcoming Investor Conferences
Bank of America Corp DE Raises Stock Position in Monte Rosa Therapeutics, Inc. $GLUE
Monte Rosa Therapeutics Announces First Patient Dosed in MODeFIRe-1, a Phase 2 Study of MRT-2359 in Combination with Apalutamide in Patients with AR Mutation-Positive Metastatic Castration-Resistant Prostate Cancer
Dimensional Fund Advisors LP Acquires 473,005 Shares of Monte Rosa Therapeutics, Inc. $GLUE
Monte Rosa Therapeutics (GLUE) Reports Q2 Loss, Misses Revenue Estimates
Monte Rosa Therapeutics Announces Second Quarter 2026 Financial Results and Business Updates
Monte Rosa Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
After a 400% Surge, Should Investors Care About This $882,000 Monte Rosa Insider Sale?
Monte Rosa: Initiating Coverage With A Buy On Degrader Platform Potential
Monte Rosa Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
Monte Rosa Therapeutics to Participate in Upcoming Investor Conferences
Monte Rosa Therapeutics (GLUE) Reports Q1 Loss, Misses Revenue Estimates
Monte Rosa Therapeutics Announces First Quarter 2026 Financial Results and Business Updates
Monte Rosa Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
Monte Rosa CEO Sells $141K in Stock Amid 300% Surge and Recent Capital Raise
Monte Rosa Therapeutics Presents Preclinical Data at American Association for Cancer Research (AACR) Annual Meeting 2026 on the Potential of its Cyclin E1 (CCNE1)-directed Molecular Glue Degrader to Treat CCNE1-amplified Solid Tumors
Monte Rosa Therapeutics, Inc. (NASDAQ:GLUE) Receives $32.80 Average PT from Analysts
Monte Rosa Therapeutics (GLUE) Reports Q4 Loss, Misses Revenue Estimates